Abstract
Biochemical and behavioral criteria were established to determine the long-term stability of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced unilateral striatal dopamine deficiency in the vervet monkey. At time points over a 12-month period, post-MPTP striatal dopamine synthesis capacity was indexed with 6-[18F]fluoro-L-DOPA (FDOPA)-positron emission tomography. For the MPTP-treated subjects (n = 4), an intrasubject FDOPA influx rate constant (K(i)) ratio method of right (lesioned) striatum left (unlesioned) striatum values was used to assess changes in striated activity. Striatal FDOPA K(i) ratios differed less than 5% between studies conducted at 1-2, 5-7, and 9-11 months post-MPTP; these results indicated a stable MPTP-induced striatal lesion over this time period. At the 5-7 and 9-11 month time points, behavioral indices of the MPTP-induced deficits were obtained within a species-typical group setting. For three of the four subjects, persistent decrements in motoric, affiliative, and vigilance behavior were observed while the frequency of aggression toward group members was increased. At the 9-11 month time point, one subject showed a 30% improvement in the social measures, indicative of a partial recovery from the MPTP-induced behavioral decrements although its striatal FDOPA K(i) ratio remained unchanged. Thus, behavioral and noninvasive biochemical methods can provide complementary indices to assess individual differences in sensitivity to MPTP-induced deficits. Both types of data are required to determine lesion stability and, subsequently, the efficacy of interventions desigued to restore normal function in this primate Parkinsonian model.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 318-329 |
| Number of pages | 12 |
| Journal | Experimental Neurology |
| Volume | 141 |
| Issue number | 2 |
| DOIs | |
| State | Published - Oct 1996 |
Fingerprint
ASJC Scopus subject areas
- Neurology
- Neuroscience(all)
Cite this
Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys. / Melega, William P.; Raleigh, Michael J.; Stout, David B.; DeSalles, Antonio A.; Cherry, Simon R; Blurton-Jones, Matthew; Morton, Grenvill G.; Huang, Sung Cheng; Phelps, Michael E.
In: Experimental Neurology, Vol. 141, No. 2, 10.1996, p. 318-329.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys
AU - Melega, William P.
AU - Raleigh, Michael J.
AU - Stout, David B.
AU - DeSalles, Antonio A.
AU - Cherry, Simon R
AU - Blurton-Jones, Matthew
AU - Morton, Grenvill G.
AU - Huang, Sung Cheng
AU - Phelps, Michael E.
PY - 1996/10
Y1 - 1996/10
N2 - Biochemical and behavioral criteria were established to determine the long-term stability of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced unilateral striatal dopamine deficiency in the vervet monkey. At time points over a 12-month period, post-MPTP striatal dopamine synthesis capacity was indexed with 6-[18F]fluoro-L-DOPA (FDOPA)-positron emission tomography. For the MPTP-treated subjects (n = 4), an intrasubject FDOPA influx rate constant (K(i)) ratio method of right (lesioned) striatum left (unlesioned) striatum values was used to assess changes in striated activity. Striatal FDOPA K(i) ratios differed less than 5% between studies conducted at 1-2, 5-7, and 9-11 months post-MPTP; these results indicated a stable MPTP-induced striatal lesion over this time period. At the 5-7 and 9-11 month time points, behavioral indices of the MPTP-induced deficits were obtained within a species-typical group setting. For three of the four subjects, persistent decrements in motoric, affiliative, and vigilance behavior were observed while the frequency of aggression toward group members was increased. At the 9-11 month time point, one subject showed a 30% improvement in the social measures, indicative of a partial recovery from the MPTP-induced behavioral decrements although its striatal FDOPA K(i) ratio remained unchanged. Thus, behavioral and noninvasive biochemical methods can provide complementary indices to assess individual differences in sensitivity to MPTP-induced deficits. Both types of data are required to determine lesion stability and, subsequently, the efficacy of interventions desigued to restore normal function in this primate Parkinsonian model.
AB - Biochemical and behavioral criteria were established to determine the long-term stability of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced unilateral striatal dopamine deficiency in the vervet monkey. At time points over a 12-month period, post-MPTP striatal dopamine synthesis capacity was indexed with 6-[18F]fluoro-L-DOPA (FDOPA)-positron emission tomography. For the MPTP-treated subjects (n = 4), an intrasubject FDOPA influx rate constant (K(i)) ratio method of right (lesioned) striatum left (unlesioned) striatum values was used to assess changes in striated activity. Striatal FDOPA K(i) ratios differed less than 5% between studies conducted at 1-2, 5-7, and 9-11 months post-MPTP; these results indicated a stable MPTP-induced striatal lesion over this time period. At the 5-7 and 9-11 month time points, behavioral indices of the MPTP-induced deficits were obtained within a species-typical group setting. For three of the four subjects, persistent decrements in motoric, affiliative, and vigilance behavior were observed while the frequency of aggression toward group members was increased. At the 9-11 month time point, one subject showed a 30% improvement in the social measures, indicative of a partial recovery from the MPTP-induced behavioral decrements although its striatal FDOPA K(i) ratio remained unchanged. Thus, behavioral and noninvasive biochemical methods can provide complementary indices to assess individual differences in sensitivity to MPTP-induced deficits. Both types of data are required to determine lesion stability and, subsequently, the efficacy of interventions desigued to restore normal function in this primate Parkinsonian model.
UR - http://www.scopus.com/inward/record.url?scp=0030272412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030272412&partnerID=8YFLogxK
U2 - 10.1006/exnr.1996.0167
DO - 10.1006/exnr.1996.0167
M3 - Article
VL - 141
SP - 318
EP - 329
JO - Experimental Neurology
JF - Experimental Neurology
SN - 0014-4886
IS - 2
ER -